Nektar Therapeutics (NASDAQ:NKTR) develops drug candidates based on its PEGylation and polymer conjugate technology platforms that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NKTR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Nektar Therapeutics could be a solid choice for investors.
Current Quarter Estimates for NKTR
In the past 30 days, three estimates have gone higher for Nektar Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 37 cents a share 30 days ago, to a loss of 35 cents today, a move of 5.4%.
Current Year Estimates for NKTR
Meanwhile, Nektar Therapeutics current year figures are also looking quite promising, with three estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 96 cents per share 30 days ago to a loss of 71 cents per share today, an increase of 21.9%.
Nektar Therapeutics Price and Consensus
Nektar Therapeutics (NKTR): Free Stock Analysis Report
Original post
Zacks Investment Research